Neoadjuvant chemotherapy: survival benefit in gastric cancer

In a phase 2 trial, Salah-Eddin Al-Batran (Institute of Clinical Cancer Research, Frankfurt, Germany) and colleagues assessed the effectiveness and feasibility of neoadjuvant fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy followed by surgery in 252 patients with metastatic...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology 2017-06, Vol.18 (6), p.e307-e307
1. Verfasser:	Das, Manjulika
Format:	Artikel
Sprache:	eng
Schlagworte:	5-Fluorouracil Adenocarcinoma Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Chemotherapy Chemotherapy, Adjuvant Clinical Trials, Phase II as Topic Disease Progression Disease-Free Survival Esophagus Gastrectomy Gastric cancer Hematology, Oncology and Palliative Medicine Humans Medical prognosis Medical research Metastases Metastasis Neoadjuvant Therapy - adverse effects Neoadjuvant Therapy - mortality Oxaliplatin Stomach Neoplasms - drug therapy Stomach Neoplasms - mortality Stomach Neoplasms - pathology Surgery Time Factors Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In a phase 2 trial, Salah-Eddin Al-Batran (Institute of Clinical Cancer Research, Frankfurt, Germany) and colleagues assessed the effectiveness and feasibility of neoadjuvant fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy followed by surgery in 252 patients with metastatic or resectable gastric or gastro-oesophageal junction adenocarcinoma. After preoperative staging, the patients...
ISSN:	1470-2045 1474-5488
DOI:	10.1016/S1470-2045(17)30321-2